微信在线咨询
| 产品编号 | 产品名称 | 产品包装 | 产品价格 |
| SM5168-10mM | 穿心莲内酯(98%, HPLC) | 10mM×0.2ml | 71.00元 |
| SM5168-25mg | 穿心莲内酯(98%, HPLC) | 25mg | 60.00元 |
| SM5168-100mg | 穿心莲内酯(98%, HPLC) | 100mg | 204.00元 |
| 中文名 | 穿心莲内酯 |
| 英文名 | Andrographolide |
| 中文别名 | - |
| 英文别名 | Andrographis |
| 来源 | 穿心莲Andrographis paniculata (Burm. f.) Nees |
| 化合物类型 | 萜类(Terpenoids)>二萜>二萜内酯 |
| 化学式 | C20H30O5 |
| 分子量 | 350.45 |
| CAS号 | 5508-58-7 |
| 纯度 | 98%, HPLC |
| 溶剂/溶解度 | Water: < 0.1 mg/ml (insoluble); DMSO: 50 mg/ml (142.67 mM) |
| 溶液配制 | 5mg加入1.43ml DMSO，或者每3.50mg加入1ml DMSO，配制成10mM溶液。 |
| 产品描述 | Andrographolide is a NF-κB inhibitor, which inhibits NF-κB activation through covalent modification of a cysteine residue on p50 in endothelial cells without affecting IκBα degradation or p50/p65 nuclear translocation. Andrographolide has antiviral effects. | ||||
| 信号通路 | - | ||||
| 靶点 | p50 | - | - | - | - |
| IC50 | NF-κB | - | - | - | - |
| 体外研究 | Andrographolide (AP) concentration-dependently suppresses receptor activator of nuclear factor kappa B ligand (RANKL)-mediated osteoclast differentiation and bone resorption in vitro and reduces the expression of osteoclast-specific markers. Andrographolide attenuates inflammation by inhibition of TNFα-induced NF-κB activation through covalent modification of reduced Cys62 of p50, without affecting IκBα degradation or p50/p65 nuclear translocation. Andrographolide also inhibits the ERK/MAPK signalling pathway without affecting p38 or JNK signalling. Andrographolide inhibits osteoclast differentiation of RAW 264.7 cells in a concentration-dependent manner. Andrographolide suppresses osteoclast formation in a concentration-dependent manner without any obvious cytotoxic effects, in both BMMs and RAW 264.7 cells. Andrographolide treatment substantially reduces the area of bone resorption. Only approximately 30% of the bone resorption observed in the control group is achieved after treatment with 2.5 μM Andrographolide. Osteoclastic bone resorption is almost completely inhibited after treatment with 10 μM Andrographolide. | ||||
| 体内研究 | Treatment with Andrographolide (5 or 30 mg/kg) reduces the extent of bone loss induced by LPS. Moreover, Andrographolide slightly increases the BMD and cortex thickness compared to LPS treatment. Histological examination confirms the protective effects of Andrographolide on LPS-induced bone loss. LPS injection leads to inflammatory bone erosion and increased numbers of TRAP-positive osteoclasts. | ||||
| 临床实验 | NCT03134443: Acute Tonsillitis, Phase 4; NCT03132623: Acute Bronchitis, Phase 4; NCT03132610: Acute Exacerbation of Chronic Bronchitis, Phase 4. | ||||
1.Zhai ZJ, et al. Br J Pharmacol. 2014,171(3):663-75.
2.Gupta S, et al. Arch Virol. 2017,162(3):611-623.
包装清单：| 产品编号 | 产品名称 | 包装 |
| SM5168-10mM | 穿心莲内酯(98%, HPLC) | 10mM×0.2ml |
| SM5168-25mg | 穿心莲内酯(98%, HPLC) | 25mg |
| SM5168-100mg | 穿心莲内酯(98%, HPLC) | 100mg |
| － | 说明书 | 1份 |
-20℃保存，至少一年有效。固体粉末4℃保存，至少一个月有效。如果溶于非DMSO溶剂，建议分装后-80℃保存，预计6个月内有效。
注意事项：本产品可能对人体有一定的毒害作用，请注意适当防护，以避免直接接触人体或吸入体内。
本产品仅限于专业人员的科学研究用，不得用于临床诊断或治疗，不得用于食品或药品，不得存放于普通住宅内。
为了您的安全和健康，请穿实验服并戴一次性手套操作。
微信在线咨询
